间质性肺疾病临床诊疗年度进展2021  

Update in interstitial lung disease 2021

作　　者：黄慧[1] Huang Hui

机构地区：[1]中国医学科学院北京协和医学院北京协和医院呼吸与危重症医学科,北京100730

出　　处：《中华结核和呼吸杂志》2022年第1期95-99,共5页Chinese Journal of Tuberculosis and Respiratory Diseases

基　　金：国家自然科学基金(81600050);中国医学科学院中央级公益性科研院所基本科研业务费临床与转化医学研究基金(2019XK320037)。

摘　　要：本文系统复习了2020年11月至2021年10月期间国内外权威杂志中关于间质性肺疾病的文献,重点关注特发性肺纤维化(IPF)患者中抗纤维化药物治疗的现状及对其预后的影响、结节病的欧洲诊疗共识和治疗推荐、过敏性肺炎的CHEST专家共识、进展型纤维化性ILD的中国专家观点、多种结缔组织疾病相关性间质性肺疾病的诊疗进展。The significant scientific advances about interstitial lung disease from November 2020 to October 2021 which were published in the Chinese and international journals were systematically reviewed in this paper.The year 2021 brought advances in our understanding of the real-world adoption of the antifibrotic medications pirfenidone and nintedanib for US idiopathic pulmonary fibrosis patients,the European statement on the diagnosis and evaluation and treatment of pulmonary fibrosis,the CHEST guideline on the diagnosis and evaluation of hypersensitivity pneumonitis,Chinese expert viewpoints on the progressive fibrosing interstitial lung disease,and international updates on the diagnosis and management of connective tissue disease-associated interstitial lung diseases.

关 键 词：间质性肺疾病 过敏性肺炎 系统复习 专家观点 结节病 临床诊疗 抗纤维化药物 进展型 

分 类 号：R563[医药卫生—呼吸系统]